

## **Short bio**

Dr. McIvor received his Ph.D. in Microbiology from the University of Minnesota in 1982. He did postdoctoral work first at the University of California, San Francisco, and then at Genentech, Inc., where he conducted early work on therapeutic gene transfer into mouse hematopoietic stem cells using retroviral vectors. He has been on the faculty at the University of Minnesota since 1986, where he has worked on the development of genetic therapies for cancer and inherited metabolic and immunodeficiency diseases using viral (retrovirus, lentivirus and AAV) and non-viral vector systems. Starting in 2006, Dr. McIvor was CEO and Chief Science Officer of Discovery Genomics, Inc. (DGI), founded in part to develop the *Sleeping Beauty* transposon system. In 2016, DGI was acquired by Immusoft Corporation based in Seattle, WA, for which Dr. McIvor now serves as Chief Development Officer. Immusoft ([immusoft.com](http://immusoft.com)) uses the *Sleeping Beauty* transposon system for genetic engineering of B cells in its platform to express therapeutic proteins for extended delivery. The platform's lead indication is mucopolysaccharidosis type I (MPS I, Hurler syndrome), for which the project has received Orphan Drug and Rare Pediatric Disease designations from the FDA and Phase II SBIR funding from the NIH.